Dejan B Budimirovic1, Elizabeth Berry-Kravis2, Craig A Erickson3, Scott S Hall4, David Hessl5, Allan L Reiss6, Margaret K King7, Leonard Abbeduto5, Walter E Kaufmann8,9. 1. Departments of Psychiatry and Behavioral Sciences, Kennedy Krieger Institute and Child Psychiatry, Johns Hopkins University School of Medicine, 716 N. Broadway, Baltimore, MD 21205 USA. 2. Departments of Pediatrics, Neurological Sciences, Biochemistry, Rush University Medical Center, 1725 West Harrison, Suite 718, Chicago, IL 60612 USA. 3. Division of Child and Adolescent Psychiatry, Cincinnati Children's Hospital Medical Center and the University of Cincinnati College of Medicine, 3333 Burnet Avenue MLC 4002, Cincinnati, OH 45229 USA. 4. Division of Interdisciplinary Brain Sciences, Department of Psychiatry and Behavioral Sciences, Stanford University, 401 Quarry Road, Stanford, CA 94305 USA. 5. MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis Medical Center, 2825 50th Street, Sacramento, CA 95817 USA. 6. Division of Interdisciplinary Brain Sciences, Departments of Psychiatry and Behavioral Sciences, Radiology and Pediatrics, Stanford University, 401 Quarry Road, Stanford, CA 94305 USA. 7. Autism & Developmental Medicine Institute, Geisinger Health System, Present address: Novartis Pharmaceuticals Corporation, US Medical, One Health Plaza, East Hanover, NJ 07936 USA. 8. Center for Translational Research, Greenwood Genetic Center, 113 Gregor Mendel Circle, Greenwood, SC 29646 USA. 9. Department of Neurology, Boston Children's Hospital, Boston, MA 02115 USA.
Abstract
OBJECTIVE: Fragile X syndrome (FXS) has been the neurodevelopmental disorder with the most active translation of preclinical breakthroughs into clinical trials. This process has led to a critical assessment of outcome measures, which resulted in a comprehensive review published in 2013. Nevertheless, the disappointing outcome of several recent phase III drug trials in FXS, and parallel efforts at evaluating behavioral endpoints for trials in autism spectrum disorder (ASD), has emphasized the need for re-assessing outcome measures and revising recommendations for FXS. METHODS: After performing an extensive database search (PubMed, Food and Drug Administration (FDA)/National Institutes of Health (NIH)'s www.ClinicalTrials.gov, etc.) to determine progress since 2013, members of the Working Groups who published the 2013 Report evaluated the available outcome measures for FXS and related neurodevelopmental disorders using the COSMIN grading system of levels of evidence. The latter has also been applied to a British survey of endpoints for ASD. In addition, we also generated an informal classification of outcome measures for use in FXS intervention studies as instruments appropriate to detect shorter- or longer-term changes. RESULTS: To date, a total of 22 double-blind controlled clinical trials in FXS have been identified through www.ClinicalTrials.gov and an extensive literature search. The vast majority of these FDA/NIH-registered clinical trials has been completed between 2008 and 2015 and has targeted the core excitatory/inhibitory imbalance present in FXS and other neurodevelopmental disorders. Limited data exist on reliability and validity for most tools used to measure cognitive, behavioral, and other problems in FXS in these trials and other studies. Overall, evidence for most tools supports a moderate tool quality grading. Data on sensitivity to treatment, currently under evaluation, could improve ratings for some cognitive and behavioral tools. Some progress has also been made at identifying promising biomarkers, mainly on blood-based and neurophysiological measures. CONCLUSION: Despite the tangible progress in implementing clinical trials in FXS, the increasing data on measurement properties of endpoints, and the ongoing process of new tool development, the vast majority of outcome measures are at the moderate quality level with limited information on reliability, validity, and sensitivity to treatment. This situation is not unique to FXS, since reviews of endpoints for ASD have arrived at similar conclusions. These findings, in conjunction with the predominance of parent-based measures particularly in the behavioral domain, indicate that endpoint development in FXS needs to continue with an emphasis on more objective measures (observational, direct testing, biomarkers) that reflect meaningful improvements in quality of life. A major continuous challenge is the development of measurement tools concurrently with testing drug safety and efficacy in clinical trials.
OBJECTIVE: Fragile X syndrome (FXS) has been the neurodevelopmental disorder with the most active translation of preclinical breakthroughs into clinical trials. This process has led to a critical assessment of outcome measures, which resulted in a comprehensive review published in 2013. Nevertheless, the disappointing outcome of several recent phase III drug trials in FXS, and parallel efforts at evaluating behavioral endpoints for trials in autism spectrum disorder (ASD), has emphasized the need for re-assessing outcome measures and revising recommendations for FXS. METHODS: After performing an extensive database search (PubMed, Food and Drug Administration (FDA)/National Institutes of Health (NIH)'s www.ClinicalTrials.gov, etc.) to determine progress since 2013, members of the Working Groups who published the 2013 Report evaluated the available outcome measures for FXS and related neurodevelopmental disorders using the COSMIN grading system of levels of evidence. The latter has also been applied to a British survey of endpoints for ASD. In addition, we also generated an informal classification of outcome measures for use in FXS intervention studies as instruments appropriate to detect shorter- or longer-term changes. RESULTS: To date, a total of 22 double-blind controlled clinical trials in FXS have been identified through www.ClinicalTrials.gov and an extensive literature search. The vast majority of these FDA/NIH-registered clinical trials has been completed between 2008 and 2015 and has targeted the core excitatory/inhibitory imbalance present in FXS and other neurodevelopmental disorders. Limited data exist on reliability and validity for most tools used to measure cognitive, behavioral, and other problems in FXS in these trials and other studies. Overall, evidence for most tools supports a moderate tool quality grading. Data on sensitivity to treatment, currently under evaluation, could improve ratings for some cognitive and behavioral tools. Some progress has also been made at identifying promising biomarkers, mainly on blood-based and neurophysiological measures. CONCLUSION: Despite the tangible progress in implementing clinical trials in FXS, the increasing data on measurement properties of endpoints, and the ongoing process of new tool development, the vast majority of outcome measures are at the moderate quality level with limited information on reliability, validity, and sensitivity to treatment. This situation is not unique to FXS, since reviews of endpoints for ASD have arrived at similar conclusions. These findings, in conjunction with the predominance of parent-based measures particularly in the behavioral domain, indicate that endpoint development in FXS needs to continue with an emphasis on more objective measures (observational, direct testing, biomarkers) that reflect meaningful improvements in quality of life. A major continuous challenge is the development of measurement tools concurrently with testing drug safety and efficacy in clinical trials.
Authors: L J Miller; D N McIntosh; J McGrath; V Shyu; M Lampe; A K Taylor; F Tassone; K Neitzel; T Stackhouse; R J Hagerman Journal: Am J Med Genet Date: 1999-04-02
Authors: C J McDougle; L Scahill; J T McCracken; M G Aman; E Tierney; L E Arnold; B J Freeman; A Martin; J J McGough; P Cronin; D J Posey; M A Riddle; L Ritz; N B Swiezy; B Vitiello; F R Volkmar; N A Votolato; P Walson Journal: Child Adolesc Psychiatr Clin N Am Date: 2000-01
Authors: Marie Moore Channell; Susan J Loveall; Frances A Conners; Danielle J Harvey; Leonard Abbeduto Journal: Am J Speech Lang Pathol Date: 2018-02-06 Impact factor: 2.408
Authors: Jessica Klusek; Carly Moser; Joseph Schmidt; Leonard Abbeduto; Jane E Roberts Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2019-08-16 Impact factor: 3.568
Authors: Jennifer L Bruno; Sm Hadi Hosseini; Amy A Lightbody; Mai K Manchanda; Allan L Reiss Journal: J Psychopharmacol Date: 2019-07-02 Impact factor: 4.153
Authors: Rihui Li; Jennifer L Bruno; Tracy Jordan; Jonas G Miller; Cindy H Lee; Kristi L Bartholomay; Matthew J Marzelli; Aaron Piccirilli; Amy A Lightbody; Allan L Reiss Journal: Biol Psychiatry Cogn Neurosci Neuroimaging Date: 2021-09-30
Authors: Maria Mody; Yoann Petibon; Paul Han; Darshini Kuruppu; Chao Ma; Daniel Yokell; Ramesh Neelamegam; Marc D Normandin; Georges El Fakhri; Anna-Liisa Brownell Journal: Sci Rep Date: 2021-08-05 Impact factor: 4.996
Authors: Laura Del Hoyo Soriano; Lauren Bullard; Angela John Thurman; Cesar Hoyos Alvarez; Leonard Abbeduto Journal: Dev Neurorehabil Date: 2021-06-25 Impact factor: 2.308